182 related articles for article (PubMed ID: 20708853)
1. Health-related quality of life after single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for prostate cancer.
Morton GC; Loblaw DA; Chung H; Tsang G; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Batchelar D; Danjoux C; Szumacher E
Int J Radiat Oncol Biol Phys; 2011 Aug; 80(5):1299-305. PubMed ID: 20708853
[TBL] [Abstract][Full Text] [Related]
2. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
Morton GC; Loblaw DA; Sankreacha R; Deabreu A; Zhang L; Mamedov A; Cheung P; Keller B; Danjoux C; Szumacher E; Thomas G
Int J Radiat Oncol Biol Phys; 2010 Jul; 77(3):811-7. PubMed ID: 19836166
[TBL] [Abstract][Full Text] [Related]
3. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. Correlation between dosimetric parameters and late rectal and urinary toxicities in patients treated with high-dose-rate brachytherapy used as monotherapy for prostate cancer.
Konishi K; Yoshioka Y; Isohashi F; Sumida I; Kawaguchi Y; Kotsuma T; Adachi K; Morimoto M; Fukuda S; Inoue T
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1003-7. PubMed ID: 19345517
[TBL] [Abstract][Full Text] [Related]
6. Acute urinary retention after I-125 prostate brachytherapy in relation to dose in different regions of the prostate.
Roeloffzen EM; Monninkhof EM; Battermann JJ; van Roermund JG; Moerland MA; van Vulpen M
Int J Radiat Oncol Biol Phys; 2011 May; 80(1):76-84. PubMed ID: 20605364
[TBL] [Abstract][Full Text] [Related]
7. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
Gore JL; Kwan L; Lee SP; Reiter RE; Litwin MS
J Natl Cancer Inst; 2009 Jun; 101(12):888-92. PubMed ID: 19509365
[TBL] [Abstract][Full Text] [Related]
8. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
Wahlgren T; Brandberg Y; Häggarth L; Hellström M; Nilsson S
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):51-9. PubMed ID: 15337539
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
11. An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer.
Frank SJ; Pisters LL; Davis J; Lee AK; Bassett R; Kuban DA
J Urol; 2007 Jun; 177(6):2151-6; discussion 2156. PubMed ID: 17509305
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
Ferrer M; Suárez JF; Guedea F; Fernández P; Macías V; Mariño A; Hervas A; Herruzo I; Ortiz MJ; Villavicencio H; Craven-Bratle J; Garin O; Aguiló F;
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):421-32. PubMed ID: 18325680
[TBL] [Abstract][Full Text] [Related]
13. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
Vargas C; Ghilezan M; Hollander M; Gustafson G; Korman H; Gonzalez J; Martinez A
J Urol; 2005 Sep; 174(3):882-7. PubMed ID: 16093980
[TBL] [Abstract][Full Text] [Related]
14. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
Albertsen PC
J Urol; 2005 Nov; 174(5):1969-70. PubMed ID: 16217368
[No Abstract] [Full Text] [Related]
15. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy.
Sarosdy MF
Cancer; 2004 Aug; 101(4):754-60. PubMed ID: 15305406
[TBL] [Abstract][Full Text] [Related]
16. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
Roeloffzen EM; Hinnen KA; Battermann JJ; Monninkhof EM; van Roermund JG; van Gellekom MP; Frank SJ; van Vulpen M
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1322-8. PubMed ID: 19939578
[TBL] [Abstract][Full Text] [Related]
17. Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding.
Akimoto T; Katoh H; Kitamoto Y; Tamaki T; Harada K; Shirai K; Nakano T
Int J Radiat Oncol Biol Phys; 2006 Jun; 65(2):364-70. PubMed ID: 16690428
[TBL] [Abstract][Full Text] [Related]
18. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
[TBL] [Abstract][Full Text] [Related]
19. Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer.
Wahlgren T; Nilsson S; Lennernäs B; Brandberg Y
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):662-70. PubMed ID: 17499452
[TBL] [Abstract][Full Text] [Related]
20. Patterns of toxicity following high-dose-rate brachytherapy boost for prostate cancer: mature prospective phase I/II study results.
Duchesne GM; Williams SG; Das R; Tai KH
Radiother Oncol; 2007 Aug; 84(2):128-34. PubMed ID: 17561293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]